Zydus Cadila has signed a collaborative research agreement with the Council of Scientific and Industrial Research (CSIR) - Institute of Microbial Technology (IMTECH), Government of India. The research partnership will primarily aim to identify new drug candidates for treatment of drug-resistant infections.
The agreement between CSIR-IMTECH and the company will see scientists from both organizations working closely together on microbiology & genomics to identify new lead candidate as novel anti-tuberculosis compounds. For this project, scientists at IMTECH will utilize their expertise and scientific knowledge in microbiology, while Zydus Cadila will provide its expertise in medicinal chemistry & pharmaceutical drug development with an aim to develop new drug combinations against drug-resistant pathogens which causes severe diseases in India and across the world.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
